[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
We describe two patients, who suffered from Stage IV gastric poorly differentiated adenocarcinoma and underwent palliative total gastrectomy, were treated by sequential chemotherapy and achieved long term-survival. The first patient was a 55-year-old male with peritoneal dissemination. After total gastrectomy, he was treated with methotrexate-5-fluorouracil (MTX/5-FU) sequential therapy for 5 months, S-1 single-agent therapy for 4 years and weekly paclitaxel (PTX) therapy for 9 months. He is being treated with irinotecan (CPT-11) therapy as an outpatient now, and has achieved 5 year 8-month survival. The second patient was a 60-year-old female. We observed unresectable metastases around the pancreas, aorta, and transverse mesocolon. She was treated with S-1 single-agent therapy for 1 year 10 months, MTX/5-FU sequential therapy for 9 months. She is now receiving weekly PTX therapy for 3 months as an outpatient and has achieved 2 year 11-month survival.
Tomimatsu
Hiroaki
H
Dept. of Surgery, Chichibu Municipal Hospital.
Nakano
Tatsuya
T
D000230:Adenocarcinoma / Q000628:therapy*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000077146:Irinotecan; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; D007166:Immunosuppressive Agents; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D017239:Paclitaxel; D005472:Fluorouracil; D002166:Camptothecin; D008727:Methotrexate